A Haplotype of the Norepinephrine Transporter (Net) Gene Slc6a2 is Associated with Clinical Response to Atomoxetine in Attention-Deficit Hyperactivity Disorder (ADHD)

Neuropsychopharmacology

Volumn 34, Issue 9, 2009, Pages 2135-2142

  Ramoz, Nicolas ^a   Boni, Claudette ^a   Downing, Anncatherine M ^b   Close, Sandra L ^b   Peters, Sandra L ^c   Prokop, Angela M ^c   Allen, Albert J ^b   Hamon, Michel ^d   Purper Ouakil, Diane ^e   Gorwood, Philip ^a,f  

^a INSERM   (France)

^b ELI LILLY AND COMPANY   (United States)

^c BioStat Solutions Inc   (United States)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e HÔPITAL ROBERT DEBRÉ   (France)

^f HÔPITAL LOUIS MOURIER   (France)

Author keywords

Attention deficit hyperactivity disorder; Linkage disequilibrium; Responder; Single nucleotide polymorphism; Slc6a2; Treatment

Indexed keywords

ATOMOXETINE; CYTOCHROME P450 2D6; NORADRENALIN TRANSPORTER;

ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG METABOLISM; DRUG RESPONSE; EXON; FEMALE; GENOME ANALYSIS; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM;

ADRENERGIC UPTAKE INHIBITORS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; COHORT STUDIES; CYTOCHROME P-450 CYP2D6; DOUBLE-BLIND METHOD; FEMALE; HAPLOTYPES; HUMANS; MALE; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPYLAMINES; SEQUENCE ANALYSIS, DNA; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 67651100726     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/npp.2009.39     Document Type: Article

References (40)

1. Barr CL, Kroft J, Feng Y, Wigg K, Roberts W, Malone M et al (2002). The norepinephrine transporter gene and attention-deficit hyperactivity disorder. Am J Med Genet 114: 255-259.
2. Barrett JC, Fry B, Maller J, Daly MJ (2005). Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21: 263-265.
3. Biederman J, Spencer T (1999). Attention-deficit/hyperactivity disorder (ADHD) as a noradrenergic disorder. Biol Psychiatry 46: 1234-1242
4. Brookes K, Xu X, Chen W, Zhou K, Neale B, Lowe N et al (2006). The analysis of 51 genes in DSM-IV combined type attention deficit hyperactivity disorder: association signals in DRD4, DAT1 and 16 other genes. Mol Psychiatry 11: 934-953.
5. Cook Jr EH, Stein MA, Krasowski MD, Cox NJ, Olkon DM, Kieffer JE et al (1995). Association of attention-deficit disorder and the dopamine transporter gene. Am J Hum Genet 56: 993-998.
6. De Luca V, Muglia P, Jain U, Kennedy JL (2004). No evidence of linkage or association between the norepinephrine transporter (NET) gene Mnll polymorphism and adult ADHD. Am J Med Genet B Neuropsychiatr Genet 124B: 38-40.
7. DuPaul GJ, Power TJ, Anastopoulos AD, Reid R (1998). ADHD Rating Scale-IV: Checklists, Norms, and Clinical Interpretation. The Guilford Press: New York.
8. Faraone SV, Perlis RH, Doyle AE, Smoller JW, Goralnick JJ, Holmgren MA et al (2005). Molecular genetics of attention-deficit hyperactivity disorder. Biol Psychiatry 57: 1313-1323.
9. Faraone S, Biederman J, Friedman D (2000). Validity of DSM-IV subtypes of attention-deficit hyperactivity disorder: a family study perspective. J Am Acad Child Adolesc Psychiatry 39: 300-307.
10. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B et al (2002). The Structure of Haplotype Blocks in the Human Genome. Science 296: 2225-2229.
11. Gao H, Zhao Y, Levine L, Allen A 2006. Determining cut-points for clinically meaningful improvement: an ROC approach. Presented at: The 53rd Annual Meeting of The American Academy of Child and Adolescent Psychiatry; October 24-29 San Diego, CA. American Academy of Child and Adolescent Psychiatry: Washington, DC, p 201.
12. Gornick MC, Addington A, Shaw P, Bobb AJ, Sharp W, Greenstein D et al (2007). Association of the dopamine receptor D4 (DRD4) gene 7-repeat allele with children with attention-deficit/hyper-activity disorder (ADHD): an update. Am J Med Genet B Neuropsychiatr Genet 144B: 379-382.
13. st ed Springer Science: New York, USA.: pp 1-24.
14. Guan L, Wang B, Chen Y, Yang L, Li J, Qian Q et al (2008). A high-density single-nucleotide polymorphism screen of 23 candidate genes in attention deficit hyperactivity disorder: suggesting multiple susceptibility genes among Chinese Han population. Mol Psychiatry e-pub ahead of print 8 January 2008
15. Hudziak JJ, Heath AC, Madden PF, Reich W, Bucholz KK, Slutske W et al (1998). Latent class and factor analysis of DSM-IV ADHD: a twin study of female adolescents. J Am Acad Child Adolesc Psychiatry 37: 848-857.
16. Kelsey DK, Sumner CR, Casat CD, Coury DL, Quintana H, Saylor KE et al (2004). Once-daily atomoxetine treatment for children with attention-deficit hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial. Pediatrics 114: e1-e8.
17. Kereszturi E, Tarnok Z, Bognar E, Lakatos K, Farkas L, Gadoros J et al (2008). Catechol-O-methyltransferase Val158Met polymorphism is associated with methylphenidate response in ADHD children. Am J Med Genet B Neuropsychiatr Genet 147B: 1431-1435.
18. Kim JW, Biederman J, McGrath CL, Doyle AE, Mick E, Fagerness J et al (2008). Further evidence of association between two NET single-nucleotide polymorphisms with ADHD. Mol Psychiatry 13: 624-630.
19. Kirchheiner J, Nickchen K, Bauer M, Wong ML, Licinio J, Roots I et al (2004). Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 9: 442-473.
20. Kooij JS, Boonstra AM, Vermeulen SH, Heister AG, Burger H, Buitelaar JK et al (2008). Response to methylphenidate in adults with ADHD is associated with a polymorphism in SLC6A3 (DAT1). Am J Med Genet B Neuropsychiatr Genet 147B: 201-208.
21. Lasky-Su J, Banaschewski T, Buitelaar J, Franke B, Brookes K, Sonuga-Barke E et al (2007). Partial replication of a DRD4 association in ADHD individuals using a statistically derived quantitative trait for ADHD in a family-based association test. Biol Psychiatry 62: 985-990.
22. Leushner J, Chiu NH (2000). Automated mass spectrometry: a revolutionary technology for clinical diagnostics. Mol Diagn 5: 341-348.
23. Levy F, Hay DA, McStephen M, Wood C, Waldman I (1997). Attention-deficit hyperactivity disorder: a category or a continuum? Genetic analysis of a large-scale twin study. J Am Acad Child Adolesc Psychiatry 36: 737-744.
24. st ed Springer Science: New York, USA. pp 231-248.
25. McEvoy B, Hawi Z, Fitzgerald M, Gill M (2002). No evidence of linkage or association between the norepinephrine transporter (NET) gene polymorphisms and ADHD in the Irish population. Am J Med Genet 114: 665-666.
26. Michelson D, Allen AJ, Busner J, Casat C, Dunn D, Kratochvil C et al (2002). Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 159: 1896-1901.
27. Michelson D, Adler L, Spencer T, Reimherr FW, West SA, Allen AJ et al (2003). Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry 53: 112-120.
28. Michelson D, Buitelaar JK, Danckaerts M, Gillberg C, Spencer TJ, Zuddas A et al (2004). Relapse prevention in pediatric patients with ADHD treated with atomoxetine: a randomized, double-blind, placebo-controlled study. J Am Acad Child Adolesc Psychiatry 43: 896-904.
29. Michelson D, Faries D, Wernicke J, Kelsey D, Kendrick K, Sallee FR et al (2001). Atomoxetine ADHD Study Group. Atomoxetine in the treatment of children and adolescents with attention-deficit hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 108: E83.
30. Michelson D, Read HA, Ruff DD, Witcher J, Zhang S, McCracken J (2007). CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD. J Am Acad Child Adolesc Psychiatry 46: 242-251.
31. Mick E, Neale B, Middleton FA, McGough JJ, Faraone SV (2008). Genome-wide association study of response to methylphenidate in 187 children with attention-deficit/hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet 147B: 1412-1418.
32. Newcorn JH, Kratochvil CJ, Allen AJ, Casat CD, Ruff DD, Moore RJ et al (2008). Atomoxetine/Methylphenidate Comparative Study Group. Atomoxetine and osmotically Released Methylphenidate for the Treatment of Attention Deficit Hyperactivity Disorder: acute Comparison and Differential Response. Am J Psychiatry 165: 721-730.
33. Polanczyk G, Zeni C, Genro JP, Guimarães AP, Roman T, Hutz MH et al (2007). Association of the adrenergic alpha2A receptor gene with methylphenidate improvement of inattentive symptoms in children and adolescents with attention-deficit hyperactivity disorder. Arch Gen Psychiatry 64: 218-224.
34. Polanczyk G, Zeni C, Genro JP, Roman T, Hutz MH, Rohde LA (2005). Attention-deficit hyperactivity disorder: advancing on pharmacogenomics. Pharmacogenomics 6: 225-234.
35. Shaw P, Gornick M, Lerch J, Addington A, Seal J, Greenstein D et al (2007). Polymorphisms of the dopamine D4 receptor clinical outcome, and cortical structure in attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 64: 921-931.
36. Smalley SL, McGough JJ, Del'Homme M, NewDelman J, Gordon E, Kim T et al (2000). Familial clustering of symptoms and disruptive behaviors in multiplex families with attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 39: 1135-1143.
37. Thapar A, Langley K, O'Donovan M, Owen M (2006). Refining the attention deficit hyperactivity disorder phenotype for molecular genetic studies. Mol Psychiatry 11: 714-720.
38. Tomalik-Scharte D, Lazar A, Fuhr U, Kirchheiner J (2008). The clinical role of genetic polymorphisms in drug-metabolizing enzymes. Pharmacogenomics J 8: 4-15.
39. Willcutt EG, Pennington BF, DeFries JC (2000). Etiology of inattention and hyperactivity/impulsivity in a community sample of twins with learning difficulties. J Abnorm Child Psychol 28: 149-159.
40. Yang L, Wang YF, Li J, Faraone SV (2004). Association of norepinephrine transporter gene with methylphenidate response. J Am Acad Child Adolesc Psychiatry 43: 1154-1158.